Hyloris Pharmaceuticals (LTS:0AB6) Loans Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
56 GF Score
Price €4.70
GF Value €10.00
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Loans Receivable?

Hyloris Pharmaceuticals LTS:0AB6 56 Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 56/100 and a GF Value™ of €10.00. The stock has 3 warning signs investors should review.

Hyloris Pharmaceuticals's Loans Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Hyloris Pharmaceuticals Loans Receivable Related Terms

Hyloris Pharmaceuticals Loans Receivable Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Loans Receivable Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0AB6
56GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Loans Receivable of €0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Loans Receivable too high?
Hyloris Pharmaceuticals' current Loans Receivable is €0.00 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Loans Receivable compare to VRTX and REGN?
Hyloris Pharmaceuticals' Loans Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Hyloris Pharmaceuticals (LTS:0AB6) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €10.00, compared to a current price of €4.70 — trading 53% below its estimated fair value. The current Loans Receivable is €0.00 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.70 is trading 53% below its estimated GF Value™ of €10.00.

Key valuation signals for LTS:0AB6:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €10.00 vs. price of €4.70 (53% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
56GF Score

Get the complete analysis for LTS:0AB6

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.70
Price
€10.00
GF Value